BRIEF published on 06/24/2025 at 20:05, 1 year 4 months ago MaaT Pharma General Meeting: Results and Appointments Kepler Cheuvreux Resolutions General Assembly MaaT Pharma Appointment Of President
PRESS RELEASE published on 06/24/2025 at 20:00, 1 year 4 months ago Inside Information / Other news releases MaaT Pharma presents Annual General Meeting results, with shareholders approving most resolutions. Jean-Marie Lefevre appointed Chairman. Liquidity contract with Kepler Cheuvreux maintained Annual General Meeting Shareholders Liquidity Contract MaaT Pharma Jean-Marie Lefevre
BRIEF published on 06/19/2025 at 19:05, 1 year 4 months ago MaaT Pharma Advances Xervyteg® Commercialization Efforts European Market Clinical Trials Oncology Microbiome Xervyteg®
PRESS RELEASE published on 06/19/2025 at 19:00, 1 year 4 months ago Inside Information / Other news releases MaaT Pharma provides business update & highlights key milestones for 2025, including MA application submission for Xervyteg, strategic focus in Europe & US trial launch Business Update Clinical-stage Biotechnology MaaT Pharma Key Milestones Xervyteg
BRIEF published on 06/13/2025 at 07:35, 1 year 4 months ago MaaT Pharma Reveals Promising Data for Xervyteg® at EHA Congress Clinical Efficacy Safety Profile Xervyteg® AGvHD EMA Application
PRESS RELEASE published on 06/13/2025 at 07:30, 1 year 4 months ago Inside Information / Other news releases MaaT Pharma presents updated positive data for Xervyteg® in treating acute Graft-versus-Host Disease at EHA Congress, validating high efficacy observed in pivotal ARES study MaaT Pharma Acute Graft-versus-Host Disease EMA Approval Xervyteg EAP Data
BRIEF published on 05/12/2025 at 07:35, 1 year 5 months ago Promising data for MaaT033 in ALS Microbiome Amyotrophic Lateral Sclerosis MaaT033 Safety And Tolerability Phase 1b Clinical Trial
BRIEF published on 04/08/2025 at 07:35, 1 year 6 months ago MaaT Pharma Announces Positive Interim Safety Results for MaaT033 Phase 2B Trial MaaT Pharma MaaT033 Allo-HSCT DSM Safety
PRESS RELEASE published on 04/08/2025 at 07:30, 1 year 6 months ago Inside Information / Other news releases MaaT Pharma announces positive safety interim analysis from DSMB for Phase 2b trial evaluating MaaT033 for patients receiving Allo-HSCT, demonstrating favorable safety profile and tolerability Phase 2B Trial MaaT Pharma Safety Analysis MaaT033 Allo-HSCT
BRIEF published on 04/07/2025 at 07:35, 1 year 6 months ago MaaT Pharma: New cover by HC Wainwright & Co Cancer Euronext Listing Microbiome Ecosystem Therapies MaaT Pharma HC Wainwright & Co
Published on 11/04/2026 at 00:05, 10 hours 42 minutes ago Scoping Study Begins for High-Grade Underground Mine Feed
Published on 11/04/2026 at 00:00, 10 hours 47 minutes ago RE Royalties Launches $5 Million Series 5 Green Bond Offering and Provides Strategic Growth Update
Published on 11/03/2026 at 23:30, 11 hours 17 minutes ago AT&T and Amdocs Expand Collaboration, Bringing Together Amdocs aOS and AT&T's AI-Enabled Framework to Simplify Operations and Improve Customer Experiences
Published on 11/03/2026 at 23:30, 11 hours 17 minutes ago GGL Resources Corp. Issues Post-Consolidation Shares to Strategic Metals Ltd.
Published on 11/04/2026 at 10:31, 15 minutes ago Original-Research: PSI SE (von First Berlin Equity Research GmbH): Accept the offer
Published on 11/04/2026 at 10:01, 45 minutes ago Komax Group aligns its organization to be consistently market-oriented
Published on 11/04/2026 at 09:15, 1 hour 31 minutes ago Fox ESS Signs Youngest Porsche Carrera Cup Germany Winner, Champion On and Off the Track
Published on 11/04/2026 at 09:15, 1 hour 31 minutes ago Omnissa expands Sovereign Solution to more markets, designed to give enterprises a safe place to run AI
Published on 11/04/2026 at 09:05, 1 hour 41 minutes ago New global Mouth-to-Body Health Institute aims to turn oral-systemic science into better prevention and care
Published on 11/03/2026 at 18:00, 16 hours 47 minutes ago Outstanding Shares and Voting Rights Monthly Statement - 31 October 2026
Published on 11/03/2026 at 17:45, 17 hours 2 minutes ago Declaration of voting rights at the end of October 2026
Published on 11/02/2026 at 18:30, 1 day 16 hours ago Disclosure of transactions in own shares from October 26 to October 30, 2026
